JNJ · Johnson & Johnson
$256.35
+0.53 (+0.21%)
At close · Jul 31
Market Cap
$616.50B
Shares
2.41B
Johnson & Johnson Earnings Call Transcripts
Every quarterly earnings call for Johnson & Johnson (JNJ) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
▼13.3%
$20.21B
$4.81B
'23 Q2
22-10-18
▼14.3%
$20.00B
$4.46B
'23 Q3
23-01-24
▲104.1%
$19.94B
$3.52B
'23 Q4
23-04-18
▲5.3%
$20.89B
−$68.00M
'24 Q1
23-07-20
▲6.5%
$21.52B
$5.14B
'24 Q2
23-10-17
▲6.8%
$21.35B
$26.03B
'24 Q3
24-01-23
▲7.3%
$21.39B
$4.05B
'24 Q4
24-04-16
▲2.3%
$21.38B
$3.25B
'25 Q1
24-05-01
▲10.3%
$23.74B
$5.54B
'25 Q2
24-10-15
▲5.2%
$22.47B
$2.69B
'25 Q3
25-01-22
▼0.8%
$21.22B
$2.58B
'25 Q4
25-04-15
▲2.4%
$21.89B
$11.00B
'26 Q1
25-07-16
▲6.6%
$25.31B
$5.53B
'26 Q2
25-10-14
▲8.4%
$23.00B
$5.12B
'26 Q4
26-01-21
LATEST
▲9.9%
$24.06B
$5.24B
'27 Q1
26-04-14
Earnings call
FY27 · Q2
2026-07-15
Johnson & Johnson Q1 FY2027 Earnings Call
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-06-09
Johnson & Johnson to Participate in the Goldman Sachs 47 th Annual Global Healthcare Conference
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-05-27
Johnson & Johnson to Participate in the Bernstein’s 42nd Annual Strategic Decisions Conference
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-05-19
Johnson & Johnson to Participate in the 2026 RBC Capital Markets Global Healthcare Conference
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-05-12
Johnson & Johnson to Participate in the Bank of America 2026 Healthcare Conference
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY27 · Q1
2026-04-14
Johnson & Johnson Q4 FY2026 Earnings Call
Confident tone
Icotride (Iketide/Tremfya) launch in psoriatic disease
Inlexo (nadofaragene) bladder cancer launch and J-code
Pipeline catalysts and upcoming readouts
Revenue
$24.06B
▲ 9.9% YoY Diluted EPS
$2.14
▼ 52.9% YoY Gross margin
66.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-03-10
Johnson & Johnson to Participate in the Barclays 28th Annual Global Healthcare Conference
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q4
2026-01-21
Johnson & Johnson Q3 FY2026 Earnings Call
Confident tone
MedTech product launches
2025 results and 2026 guidance
R&D pipeline and approvals
Revenue
$23.00B*
▲ 8.4% YoY Gross margin
67.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY26 · Q2
2025-10-14
Johnson & Johnson Q2 FY2026 Earnings Call
Revenue
$25.31B
▲ 6.6% YoY Diluted EPS
$2.27
▼ 0.9% YoY Gross margin
68.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY26 · Q1
2025-07-16
Johnson & Johnson Q1 FY2026 Earnings Call
Confident tone
Immunology franchise with ICOTYDE and TREMFYA
MedTech and surgery platform
Innovative Medicine growth and oncology portfolio
Revenue
$21.89B
▲ 2.4% YoY Diluted EPS
$4.54
▲ 238.8% YoY Gross margin
66.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2025-04-15
Johnson & Johnson Q4 FY2025 Earnings Call
Confident tone
2026 Financial Guidance
MedTech Portfolio & New Launches
Talc Litigation
Revenue
$21.22B*
▼ 0.8% YoY Gross margin
70.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-01-22
Johnson & Johnson Q3 FY2025 Earnings Call
Revenue
$22.47B
▲ 5.2% YoY Diluted EPS
$1.11
▼ 89.1% YoY Gross margin
69.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2024-10-15
Johnson & Johnson Q2 FY2025 Earnings Call
Revenue
$23.74B
▲ 10.3% YoY Diluted EPS
$2.29
▲ 16.8% YoY Gross margin
67.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2024-05-01
Johnson & Johnson Q1 FY2025 Earnings Call
Revenue
$21.38B
▲ 2.3% YoY Diluted EPS
$1.34
Gross margin
69.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2024-04-16
Johnson & Johnson Q4 FY2024 Earnings Call
Confident tone
MedTech performance and innovation
Innovative Medicine growth and pipeline
M&A and capital allocation
Revenue
$21.39B
▲ 7.3% YoY Diluted EPS
$1.67
▲ 25.6% YoY Gross margin
68.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-01-23
Johnson & Johnson Q3 FY2024 Earnings Call
Revenue
$21.35B
▲ 6.8% YoY Diluted EPS
$10.21
▲ 507.7% YoY Gross margin
69.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2023-10-17
Johnson & Johnson Q2 FY2024 Earnings Call
Revenue
$21.52B
▲ 6.5% YoY Diluted EPS
$1.96
▲ 8.9% YoY Gross margin
70.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2023-07-20
Johnson & Johnson Q1 FY2024 Earnings Call
Revenue
$20.89B
▲ 5.3% YoY Diluted EPS
$-0.03
▼ 101.6% YoY Gross margin
68.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2023-04-18
Johnson & Johnson Q4 FY2023 Earnings Call
Revenue
$19.94B
▲ 104.1% YoY Diluted EPS
$1.33
Gross margin
69.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-01-24
Johnson & Johnson Q3 FY2023 Earnings Call
Revenue
$20.00B
▼ 14.3% YoY Diluted EPS
$1.68
▲ 22.6% YoY Gross margin
69.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2022-10-18
Johnson & Johnson Q2 FY2023 Earnings Call
Revenue
$20.21B
▼ 13.3% YoY Diluted EPS
$1.80
▼ 23.4% YoY Gross margin
68.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2022-07-19
Johnson & Johnson Q1 FY2023 Earnings Call
Revenue
$19.84B
▼ 11.1% YoY Diluted EPS
$1.93
▼ 16.8% YoY Gross margin
69.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2022-04-19
Johnson & Johnson Q4 FY2022 Earnings Call
Revenue
$9.77B*
▼ 56.5% YoY Gross margin
84.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-01-25
Johnson & Johnson Q3 FY2022 Earnings Call
Revenue
$23.34B
▲ 10.7% YoY Diluted EPS
$1.37
▲ 3% YoY Gross margin
68.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2021-10-19
Johnson & Johnson Q2 FY2022 Earnings Call
Revenue
$23.31B
▲ 27.1% YoY Diluted EPS
$2.35
▲ 72.8% YoY Gross margin
67.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2021-07-21
Johnson & Johnson Q1 FY2022 Earnings Call
Revenue
$22.32B
▲ 7.9% YoY Diluted EPS
$2.32
▲ 6.9% YoY Gross margin
68.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2021-04-20
Johnson & Johnson Q4 FY2021 Earnings Call
Revenue
$22.48B*
▲ 8.3% YoY Gross margin
65.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-01-26
Johnson & Johnson Q3 FY2021 Earnings Call
Revenue
$21.08B
▲ 1.7% YoY Diluted EPS
$1.33
▲ 101.5% YoY Gross margin
66.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2020-10-13
Johnson & Johnson Q2 FY2021 Earnings Call
Revenue
$18.34B
▼ 10.8% YoY Diluted EPS
$1.36
▼ 34.6% YoY Gross margin
64.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2020-07-16
Johnson & Johnson Q1 FY2021 Earnings Call
Revenue
$20.69B
▲ 3.3% YoY Diluted EPS
$2.17
▲ 56.1% YoY Gross margin
65.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2020-04-14
Johnson & Johnson Q4 FY2020 Earnings Call
Revenue
$20.75B
▲ 1.7% YoY Diluted EPS
$1.50
▲ 33.9% YoY Gross margin
65.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-01-22
Johnson & Johnson Q3 FY2020 Earnings Call
Revenue
$20.73B
▲ 1.9% YoY Diluted EPS
$0.66
▼ 54.2% YoY Gross margin
66.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q1
2019-04-30
Johnson & Johnson Q1 FY2020 Earnings Call
Revenue
$20.02B
▲ 0.1% YoY Diluted EPS
$1.39
▼ 13.1% YoY Gross margin
67.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Showing 1–33 of 33 earnings calls
Key facts
CIK
200406
CUSIP
478160104
13F (30d)
2292 filings
2245 filers
Visit website
Investor relations